ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2966

Assessment of Damage in Behcet’s Disease: Do We Need a Specific Damage Index?

Ali Ugur Unal1, Hale Gulcin Yildirim2, Ceylan Cikikci2, Gulsen Ozen3, Nevsun Inanc3, Pamir Atagunduz3, Tulin Ergun4 and Haner Direskeneli5, 1Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, 2Marmara University Faculty of Medicine, Istanbul, Turkey, 3Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 4Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, 5Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Behcet's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Vasculitis - Poster III: Rarer Vasculitides

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Behcet’s Disease (BD) is a systemic vasculitis characterized by involvement of vessels of any size and type. In the course systemic vasculitis, it is important to distinguish disease activity from damage to prevent unnecessary immunosuppression. Damage is also an important surrogate for long-term outcome in vasculitis. Although a well-established validated damage index, “vasculitis damage index” (VDI) is available for vasculitis, its performance in BD has never been assessed.  In this study we assessed the damage in BD by using VDI, to determine whether VDI covers all BD-associated damage and lastly to develop a preliminary BD-specific damage index with the obtained data.

Methods: A total of 139 consecutive patients with BD (F/M: 58/81, mean age 38.9±10.9 yrs, disease duration 9.5±7.4 yrs)  from a single center were evaluated for damage in a cross-sectional study using the VDI. Considering the patients data and items of VDI with further literature search for BD-specific damages, new items (detailed cardiovascular, ocular, and vascular involvement-, particularly venous disease-related damages) were added to VDI. This modified VDI (Behcet’s Disease-VDI [B-VDI]) was also scored in allpatients.

Results: Seventy seven patients (55.4%) had major organ involvement and 105 (75.5%) patients were on immunosupressive (IS) treatment (Table 1). The mean VDI score was 0.3±0.7 and majority of the patients had score “0” (“0” in 107 [77%], “1” in 22 [15.8%], “2” in 7 [5%], “3” in 1 [0.7%], and “4” in 2 [1.4%] patients).  The mean B-VDI score was 0.6±1.1 (“0” in 92 [66.2%], “1” in 25 [18%], “2” in 13 [9.4%], “3” in 4 [2.9%] and “4” in 3 [2.2%] patients, “5” in 1 [0.7%], and “6” in 1 [0.7%] patient) and was significantly higher than VDI (p<0.001). The main difference between VDI and B-VDI was in vascular (0.05±0.2 vs 0.3±0.6, p<0.001) damage items. Both VDI and B-VDI scores were significantly higher in patients with major organ involvement compared to mucocutaneous BD. Both scores were also positively correlated with the age, disease duration and total duration of IS treatment. When individual organ items evaluated, it was observed that damage in patients with major organ involvement was predominantly associated with ocular and vascular involvements. Although VDI-eye and B-VDI-eye scores were not significantly different (both 0.3±0.6, p=0.32), B-VDI-vascular scores were significantly higher than VDI-vascular scores both in the entire cohort and in patients with major organ involvement (0.6±0.8 vs 0.1±0.3, p<0.001).

Conclusion: Both VDI and B-VDI capture reliable data on damage among patients with BD. However, VDI does not cover all vascular involvement-related damages of BD. Addition of new items, especially about vascular damage, to VDI will provide more comprehensive damage assessment in BD. Further prospective followup is required to determine the prognostic value of these damage indices in BD.    


Disclosure: A. U. Unal, None; H. G. Yildirim, None; C. Cikikci, None; G. Ozen, None; N. Inanc, None; P. Atagunduz, None; T. Ergun, None; H. Direskeneli, None.

To cite this abstract in AMA style:

Unal AU, Yildirim HG, Cikikci C, Ozen G, Inanc N, Atagunduz P, Ergun T, Direskeneli H. Assessment of Damage in Behcet’s Disease: Do We Need a Specific Damage Index? [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/assessment-of-damage-in-behcets-disease-do-we-need-a-specific-damage-index/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-damage-in-behcets-disease-do-we-need-a-specific-damage-index/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology